Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Treatment of patients with type 2 diabetes (T2D) with the drug metformin greatly reduces diabetic complications and mortality.
Unfortunately, many patients on metformin therapy become hyperglycemic, which exacerbates insulin resistance and reduces β cell function.
Dugs that target the sodium-glucose cotransporter-2 (SGLT2), which promotes glucose absorption in the kidney have been attractive for use a add-ons to metformin treatment.
In this issue of theJournal of Clinical Investigation, two research groups led by Ralph DeFronzo of the University of Texas and Ele Ferrannini of the University of Pisa independently report on clinical studies testing the ability SGLT2 inhibitors to reduce plasma glucose levels in T2D patients. SGLT2 inhibition increased glucose excretion in the urine (glycosuria), lowered fasting plasma glucose, and improved tissue insulin sensitivity. Surprisingly, the use of SLGT2 inhibitors resulted in an increase in endogenous glucose production and decreased insulin secretion, though overall pancreatic β cell function was improved.
In a companion Commentary, William Cefalu of the Pennington Biomedical Research Center discusses the implications of these clinical studies for the future of T2D treatment.
ACCOMPANYING ARTICLE TITLE: Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Diabetes category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Journal of Clinical Investigation. "Hyperglycemia improved but glucose production increased by Inhibition of kidney glucose transport." Medical News Today. MediLexicon, Intl., 29 Jan. 2014. Web.
17 Apr. 2014. <http://www.medicalnewstoday.com/releases/271792>
Journal of Clinical Investigation. (2014, January 29). "Hyperglycemia improved but glucose production increased by Inhibition of kidney glucose transport." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271792.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.